Search results for "Staging."

showing 10 items of 715 documents

Could JC virus provoke metastasis in colon cancer?

2014

AIM: To evaluate the prevalence of John Cunningham virus (JC virus) in a small cohort of patients with colon cancer and to assess its presence in hepatic metastasis. METHODS: Nineteen consecutive patients with histologically diagnosed colon cancer were included in our study, together with ten subjects affected by histologically and serologically diagnosed hepatitis C virus infection. In the patients included in the colon cancer group, JC virus was searched for in the surgical specimen; in the control group, JC virus was searched for in the hepatic biopsy. The difference in the prevalence of JC virus in the hepatic biopsy between the two groups was assessed through the χ2 test. RESULTS: Four…

MalePathologymedicine.medical_specialtyColorectal cancerHepatitis C virusvirusesBiopsyJC virusmedicine.disease_causePolymerase Chain ReactionVirusMetastasisRisk FactorsmedicinePrevalenceHumansAgedNeoplasm StagingRetrospective StudiesAged 80 and overSettore MED/12 - GastroenterologiaPolyomavirus InfectionsChi-Square Distributionmedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyJC Virus InfectionGeneral MedicineHepatitis CCase Control StudyMiddle Agedmedicine.diseaseJC VirushumanitiesSettore MED/18 - Chirurgia GeneraleTumor Virus InfectionsItalyLiver biopsyColonic NeoplasmsDNA ViralFemalecolon cancer John Cunnungham virus metastasisbusiness
researchProduct

The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer.

2007

The blood group antigen Lewis Y is expressed on epithelial tumors of the respiratory, digestive and reproductive system. Despite being regarded as an attractive target for immunotherapy, its function is still not well defined and its prognostic value remains a subject of discussion. Eighty-three paraffin-embedded tissue sections of non-small cell lung cancer (NSCLC) patients in stage I-IIIa, who underwent surgical resection of the primary tumor (73% male; 43% adenocarcinoma), were stained with a new, highly specific monoclonal antibody against Lewis Y (clone A70-C/C8). A positive Lewis Y expression was observed in 51% of patients; adenocarcinomas were favorably stained (67%). Multivariate a…

MalePathologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classmedicine.medical_treatmentMonoclonal antibodyABO Blood-Group SystemImmunoenzyme TechniquesLewis Blood Group AntigensAntigenAntigens NeoplasmCarcinoma Non-Small-Cell LungmedicineCarcinomaBiomarkers TumorHumansReproductive systemRespiratory systemLung cancerSurvival rateNeoplasm Stagingbusiness.industryGeneral MedicineImmunotherapyMiddle Agedmedicine.diseasePrognosisSurvival RatebusinessFollow-Up StudiesTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
researchProduct

Bladder tumor staging: comparison of contrast-enhanced and gray-scale ultrasound

2009

OBJECTIVE. The purpose of this study was to evaluate the effectiveness of contrast-enhanced sonography in comparison with conventional sonography in differentiating muscle- infiltrating and superficial neoplasms of the urinary bladder. SUBJECTS AND METHODS. Conventional and contrast-enhanced sonography were performed on 34 consecutively registered patients with bladder tumors. All examinations were reviewed by two independent sonologists. At gray-scale sonography, interruption of the hyperechoic bladder wall was considered the main diagnostic criterion for differentiating superficial and infiltrating tumors. At contrast-enhanced sonography, a tumor was considered superficial when the hypoen…

MalePathologymedicine.medical_specialtytumorUrinary systemcontrast agent; staging; tumor; ultrasonography; ultrasound; urinary bladderContrast MediaDiagnosis DifferentialImage Interpretation Computer-AssistedBladder tumorMedicineHumansRadiology Nuclear Medicine and imagingNeoplasm InvasivenessAgedNeoplasm StagingUrinary bladdermedicine.diagnostic_testbusiness.industryultrasoundUltrasoundGeneral MedicineCystoscopyCystoscopystagingultrasonographyMiddle Agedcontrast agentmedicine.diseaseBladder tumor stagingGray scale ultrasoundmedicine.anatomical_structureROC CurveUrinary Bladder NeoplasmsFemaleRadiologyDifferential diagnosisbusinessInfiltration (medical)urinary bladder
researchProduct

TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.

2004

The aim of this study was to clarify whether specific p53 mutations may have biological relevance in terms of disease relapse or death in gastric carcinomas (GC). Resected specimens from a consecutive series of 62 patients with GC undergoing potentially curative surgery were prospectively studied. The mutational status of exons 5-8 of the p53 gene was investigated in 62 cases using the PCR-SSCP and sequencing. Presence of microsatellite instability (MSI) was evaluated in 56 cases by analyzing loci highly sensitive of MSI. Twenty mutations of p53 were detected in 17 of the 62 cases analyzed (27%). Ten mutations (50%) occurred in highly conserved domains. According to the p53 specific functio…

MalePhysiologyClinical BiochemistryBiologyBioinformaticsExonchemistry.chemical_compoundAge DistributionStomach NeoplasmsmedicineHumansCancer mutationsTP53Prospective StudiesProspective cohort studyGeneSurvival analysisPolymorphism Single-Stranded ConformationalAgedNeoplasm StagingCarcinomaMicrosatellite instabilityCell BiologyDNA-binding domainDNA NeoplasmExonsMiddle Agedmedicine.diseaseGenes p53PrognosisSurvival AnalysisProtein Structure TertiarychemistryItalyMutationCancer researchFemaleDNAFollow-Up StudiesMicrosatellite RepeatsJournal of cellular physiology
researchProduct

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

2015

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatmen…

MalePredictive Value of TestGastroenterologyCohort StudiesAntineoplastic AgentProspective StudiesProspective cohort studyMultivariate AnalysiLiver NeoplasmsHepatitis CMiddle AgedSorafenibItalyLiver NeoplasmHepatocellular carcinomaFemaleSurvival Analysimedicine.drugHumanSorafenibNiacinamidePhenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsSettore MED/12 - GASTROENTEROLOGIAReproducibility of ResultAntineoplastic AgentsRisk AssessmentPredictive Value of TestsInternal medicinemedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingNeoplasm InvasiveneAnalysis of VarianceHepatologyPerformance statusbusiness.industryPhenylurea CompoundsPatient SelectionCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularHepatologymedicine.diseaseSurvival AnalysisSurgeryDiscontinuationProspective StudieWithholding TreatmentMultivariate AnalysisCohort StudiebusinessDrug-Related Side Effects and Adverse Reaction
researchProduct

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation.

2014

Background: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. Methods: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach’s alpha.…

MalePsychometricsAparell urinariSurveys and QuestionnairesProspective cohort studyCàncermedia_commonLanguageCognitionGeneral MedicinePatient outcomeControl de qualitatNeoplasias de la Vejiga UrinariaEstudios de ValidaciónPsicometríaBufeta -- CàncerFemalePsicometriaClinical psychologyCross-Cultural ComparisonQuality of lifemedicine.medical_specialtyPsychometricsUrinary bladder neoplasms:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychological Tests::Psychometrics [Medical Subject Headings]:Publication Characteristics::Study Characteristics::Validation Studies [Medical Subject Headings]Cronbach's alpha:Disciplines and Occupations::Social Sciences::Quality of Life [Medical Subject Headings]medicine:Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms [Medical Subject Headings]media_common.cataloged_instanceHumansEuropean UnionEuropean unionAgedNeoplasm StagingGynecologyAnalysis of VarianceBladder cancerbusiness.industryResearchPublic Health Environmental and Occupational HealthConstruct validityTranslatingmedicine.diseaseCross-cultural studiesUnited StatesValidation studiesPatient outcomesCalidad de VidabusinessHealth and quality of life outcomes
researchProduct

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with che…

2013

Abstract Introduction Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-naive patients with metastatic/unresectable non-small cell lung cancer (NSCLC). Methods Patients with histologically or cytologically confirmed NSCLC stage IIIB/IV disease by RECIST (version 1.0) and ECOG-PS 0–1 were enrolled at 15 European sites. Patients received tigatuzumab or placebo intravenously with carboplatin/paclitaxel every 3 weeks (1 cycle) for up to 6 cycles. The primary end point was progression-free survival (PFS). Sec…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPaclitaxelmedicine.medical_treatmentPhases of clinical researchNeutropeniaAntibodies Monoclonal HumanizedPlaceboGastroenterologyDisease-Free SurvivalCarboplatinPlaceboschemistry.chemical_compoundDouble-Blind MethodCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisTigatuzumabLung cancerNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseCarboplatinSurgeryEuropeReceptors TNF-Related Apoptosis-Inducing LigandOncologychemistryPaclitaxelFemalebusinessLung Cancer
researchProduct

Treatment of soft tissue sarcoma in childhood and adolescence: A report of the german cooperative soft tissue sarcoma study

1992

Background In the first German soft tissue sarcoma (STS) study, CWS-81, 344 patients younger than 19 years of age who had previously untreated soft tissue sarcoma were studied. For this analysis, there were 218 patients with chemosensitive STS (Group A: rhabdomyosarcoma [RMS], synovial sarcoma, extraosseous Ewing sarcoma, leiomyosarcoma, undifferentiated sarcoma, and malignant peripheral neuroectodermal tumor) who could be studied for a minimum potential follow-up time of 6 years. Methods A staging system based on the postoperative extent of the disease was used. The chemotherapy for Stage I-III disease consisted of vincristine, dactinomycin, cyclophosphamide, and doxorubicin (VACA). Patien…

MaleReoperationLeiomyosarcomaCancer Researchmedicine.medical_specialtyVincristineAdolescentmedicine.medical_treatmentSoft Tissue NeoplasmsGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildRhabdomyosarcomaCyclophosphamideSurvival rateNeoplasm StagingChemotherapybusiness.industrySoft tissue sarcomaSarcomaPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisSynovial sarcomaSurgeryOncologyChemotherapy AdjuvantDoxorubicinVincristineChild PreschoolDactinomycinRegression AnalysisFemaleSarcomabusinessFollow-Up Studiesmedicine.drugCancer
researchProduct

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated w…

2002

Background: K-ras mutations, one of the earliest events observed in colorectal carcinogenesis, are mostly found in codons 12 and 13, and less frequently in codon 61, all three of which are estimated to be critical for the biological activity of the protein. Nevertheless the prognostic significance of such mutations remains controversial. Our purpose was to assess whether any or specific K-ras mutations in primary colorectal cancer had prognostic significance and were linked to clinico-pathological parameters. Patients and methods: Paired tumor and normal tissue samples from a consecutive series of 160 untreated patients (median of follow up 71 months), undergoing resective surgery for prima…

MaleSettore MED/06 - Oncologia MedicaColorectal cancermedicine.disease_causePolymerase Chain ReactionMetastasisProspective StudiesMutationTransition (genetics)Biopsy NeedleDNA NeoplasmHematologyMiddle AgedFlow CytometryPrognosisColorectal carcinomaOncologyFemaleColorectal NeoplasmsAdultGenetic Markersmedicine.medical_specialtyK-ras mutationAdenocarcinomaSensitivity and SpecificityPredictive Value of TestsCulture TechniquesInternal medicineCarcinomamedicineHumansCodonGeneAgedNeoplasm StagingProbabilityProportional Hazards ModelsAnalysis of VarianceProportional hazards modelbusiness.industrymedicine.diseaseDNA ploidyGenes rasLogistic ModelsEndocrinologyGenetic markerMultivariate AnalysisMutationCancer researchbusinessAnnals of Oncology
researchProduct

Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.

2015

Abstract Objectives To compare whole body-MRI (WB-MRI) with diffusion-weighted imaging and FDG-PET/CT in staging newly diagnosed FDG-avid lymphomas. Methods 68 patients (37 males, 31 females; median age 42 years; range 15–86 years) with histologically confirmed lymphoma (37 Classical Hodgkin, 16 Diffuse large B-cell, 10 Follicular, 5 Mantle cell) underwent both MRI and FDG-PET/CT before treatment. Ann Arbor stages obtained with WB-MRI and FDG-PET/CT were compared using Cohen’s k statistics. Moreover WB-MRI and FDG-PET/CT stages were compared with the pathological stages obtained after the diagnostic iter using also bone marrow and available biopsies if clinically indicated. Results The agre…

MaleStagingLymphomaMultimodal Imaging030218 nuclear medicine & medical imaging0302 clinical medicineWhole Body ImagingProspective StudiesStage (cooking)Computed tomographyAged 80 and overmedicine.diagnostic_testGeneral MedicineMiddle AgedPositron emission tomography030220 oncology & carcinogenesisRadiopharmaceuticalFemaleDiffusion-weighted imagingRadiologyHumanmedicine.drugAdultmedicine.medical_specialtyAdolescentWhole body imagingReproducibility of ResultYoung Adult03 medical and health sciencesMagnetic resonance imagingFluorodeoxyglucose F18medicineHumansRadiology Nuclear Medicine and imagingAgedNeoplasm StagingFluorodeoxyglucosePET-CTIvermectinbusiness.industryReproducibility of ResultsMagnetic resonance imagingmedicine.diseaseLymphomaProspective StudieDiffusion Magnetic Resonance ImagingPositron-Emission TomographyMantle cell lymphomaRadiopharmaceuticalsSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedNuclear medicinebusinessEuropean Journal of Radiology
researchProduct